Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcin Kowanetz

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical Lung Cancer|June 27, 2020
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung CancerAnne C Chiang, Lecia Van Dam Sequist, Jill Gilbert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2017
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural MesotheliomaNamrata S Patil, Luisella Righi, Hartmut Koeppen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2013
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitmentVernon T Phan, Xiumin Wu, Jason H Cheng, et al.
Frontiers in Immunology|September 26, 2022
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancerDavid G Coffey, Yuexin Xu, Andrea M H Towlerton, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Journal of Translational Medicine|March 26, 2013
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaCongfen Li, Chikara Takahashi, Liangxuan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Lung Cancer|June 27, 2020
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung CancerAnne C Chiang, Lecia Van Dam Sequist, Jill Gilbert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2017
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural MesotheliomaNamrata S Patil, Luisella Righi, Hartmut Koeppen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2013
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitmentVernon T Phan, Xiumin Wu, Jason H Cheng, et al.
Frontiers in Immunology|September 26, 2022
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancerDavid G Coffey, Yuexin Xu, Andrea M H Towlerton, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Journal of Translational Medicine|March 26, 2013
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaCongfen Li, Chikara Takahashi, Liangxuan Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I studyLeora Horn, Scott N Gettinger, Michael S Gordon, et al.
Pageof 5